Harbor Human Capital Factor US Small Cap ETF(HAPS.US)

Company Encyclopedia
View More
name
Harbor Human Capital Factor US Small Cap ETF
HAPS.US
News
View More

Did KT-621 Fast Track Status Just Shift Kymera Therapeutics' (KYMR) Investment Narrative?

Kymera Therapeutics announced positive Phase 1b results for KT-621 in atopic dermatitis and received FDA Fast Track designation. This could reshape expectations for Kymera's protein degradation platform. The company also completed a $602 million equity offering to support KT-621's Phase 2b and 3 programs. However, high cash burn and reliance on future trial success remain risks. Kymera's narrative projects $82.2 million revenue and $13.0 million earnings by 2028, with a fair value estimate of $114 per share.

Simplywall·
US
KYMR
+1.45%
Simplywall·
US
KYMR
+1.45%

PTC Therapeutics Wins Japan Approval for Sephience to Treat PKU

PTC Therapeutics Inc. has received approval from Japan's Ministry of Health for Sephience™ to treat phenylketonuria (PKU) in all age groups. This marks PTC's first product approval in Japan. Pricing discussions are expected to conclude by Q1 2026, followed by the product launch. The news was originally published by PTC via PR Newswire on December 22, 2025.

Reuters·
US
PTCT
-0.08%
Reuters·
US
PTCT
-0.08%

Kymera Therapeutics (KYMR): Valuation Check After KT-621 Phase 1b Success and FDA Fast Track Nod

Kymera Therapeutics (KYMR) has reported positive Phase 1b data for its STAT6 degrader KT-621 in atopic dermatitis and received an FDA Fast Track designation. This has contributed to a 29.57% 30-day share price return and a 105.40% year-to-date return. Despite recent fundraising and trading below consensus targets, Kymera is seen as undervalued with a fair value estimate of $114, suggesting potential upside. However, risks include high R&D spending and reliance on KT-621's success.

Simplywall·
US
KYMR
+1.45%
Simplywall·
US
KYMR
+1.45%

BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026

RBC Capital Markets reports a strong rebound in the biotech sector since April 2025, driven by clinical data and new drug launches. M&A activity is booming, with $101B in deals in 2025. The funding environment has improved, with successful IPOs and increased financing. Despite policy fears, regulatory volatility persists. RBC highlights Kymera Therapeutics, Apogee Therapeutics, Xenon Pharmaceuticals, and Ascendis Pharma as potential acquisition targets.

Reuters·
US
ASND
-1.81%
US
KYMR
+1.45%
US
XENE
-1.89%
Reuters·
US
ASND
-1.81%
US
KYMR
+1.45%
US
XENE
-1.89%

Baker Bros. Advisors LP Reports Acquisition of Kymera Therapeutics Inc. Common Shares

Baker Bros. Advisors LP has acquired common shares of Kymera Therapeutics Inc. Felix J. Baker, a director at Kymera, is listed among the beneficial owners. The acquisition details were filed with the U.S. SEC and can be accessed via EDGAR. This AI-generated news brief is for informational purposes only and not financial advice.

Reuters·
US
KYMR
+1.45%
Reuters·
US
KYMR
+1.45%
© 2026 Longbridge｜Disclaimer